PubRank

Everardo Cobos

Author PubWeight™ 54.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics 2005 1.70
2 Nanotechnology and human health: risks and benefits. J Appl Toxicol 2010 1.15
3 Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 2011 1.11
4 AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008 1.11
5 Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol 2011 1.06
6 p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol 2010 1.06
7 Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007 1.05
8 Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line. Exp Hematol 2002 0.94
9 Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol 2011 0.93
10 Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003 0.93
11 Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis 2009 0.92
12 Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 2005 0.92
13 Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 2010 0.89
14 Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med 2004 0.89
15 Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 2006 0.89
16 Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol 2007 0.89
17 Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis 2008 0.87
18 Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One 2011 0.86
19 Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci 2007 0.85
20 Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett 2011 0.85
21 Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One 2012 0.85
22 Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model 2006 0.84
23 Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol 2012 0.84
24 Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother 2011 0.84
25 Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med 2009 0.84
26 Practical model for psychosocial care. J Oncol Pract 2009 0.83
27 Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. BMC Cancer 2011 0.83
28 Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol 2012 0.83
29 Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother 2013 0.83
30 Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother 2008 0.83
31 Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol 2015 0.83
32 CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. J Biol Chem 2011 0.82
33 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [corrected] induces CRM1-dependent p53 nuclear accumulation in human bronchial epithelial cells. Toxicol Sci 2010 0.82
34 Application of vitamin D and derivatives in hematological malignancies. Cancer Lett 2011 0.82
35 Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls. Proteomics Clin Appl 2009 0.81
36 Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther 2005 0.81
37 The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med 2008 0.81
38 Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep 2009 0.81
39 Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol 2007 0.81
40 The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol 2014 0.81
41 rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol 2008 0.80
42 CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model. Oncol Rep 2011 0.80
43 Sperm fibrous sheath proteins: a potential new class of target antigens for use in human therapeutic cancer vaccines. Cancer Immun 2008 0.79
44 Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology 2010 0.79
45 Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clin Appl Thromb Hemost 2007 0.79
46 The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 2007 0.79
47 Repression and coactivation of CCAAT/enhancer-binding protein epsilon by sumoylation and protein inhibitor of activated STATx proteins. J Biol Chem 2005 0.78
48 Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk Lymphoma 2011 0.78
49 Selective expression and immunogenicity of the cancer/testis antigens SP17, AKAP4 and PTTG1 in non-small cell lung cancer: new candidates for active immunotherapy. Chest 2014 0.78
50 Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Mol Biol Rep 2009 0.78
51 Genistein and hematological malignancies. Cancer Lett 2010 0.78
52 Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol 2015 0.77
53 A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. J Immunol Methods 2007 0.77
54 Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol 2014 0.77
55 Pituitary tumor transforming gene 1 in the liver. Hepatology 2006 0.77
56 Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol 2012 0.77
57 Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection. Curr Cancer Drug Targets 2015 0.76
58 Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis. Thromb Res 2012 0.76
59 Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol 2011 0.76
60 An update on hematological malignancies. Tex Med 2010 0.76
61 Immunological treatment of liver tumors. World J Gastroenterol 2005 0.75
62 Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med 2008 0.75
63 The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC). Anticancer Res 2002 0.75
64 Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol 2002 0.75
65 Targeting Tumor Initiating Cells through Inhibition of Cancer Testis Antigens and Notch Signaling: A Hypothesis. Int Rev Immunol 2015 0.75
66 Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol 2011 0.75
67 Epidermolysis bullosa acquisita occurring in 2 patients with hepatitis C. J Am Acad Dermatol 2006 0.75
68 Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer? Clin Appl Thromb Hemost 2004 0.75